Tax-cover sale by Sagimet (SGMT) CFO Thierry Chauche disclosed

Rhea-AI Filing Summary

Sagimet Biosciences Chief Financial Officer Thierry Chauche reported an automatic sale of Series A Common Stock largely tied to tax obligations. On February 10, 2026, he sold 1,312 shares at $5.3603 per share in an open-market transaction.

According to the disclosure, the shares were required to be sold to cover tax withholding arising from the vesting of restricted stock units, and the sales were automatic rather than discretionary. After this transaction, Chauche directly beneficially owned 15,688 shares of Sagimet Biosciences common stock.

Insider Trade Summary

Net Seller: 1,312 shares ($7,033)

Net Sell 1 txn

Insider Chauche Thierry

Role Chief Financial Officer

Sold 1,312 shs ($7K)

Type	Security	Shares	Price	Value
Sale	Series A Common Stock	1,312	$5.3603	$7K

Holdings After Transaction: Series A Common Stock — 15,688 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chauche Thierry

(Last) (First) (Middle)

SAGIMET BIOSCIENCES INC.

155 BOVET RD., SUITE 303

(Street)

SAN MATEO CA 94402

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Series A Common Stock	02/10/2026		S(1)		1,312	D	$5.3603	15,688	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

	/s/ Elizabeth Rozek, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Sagimet Biosciences (SGMT) report on this Form 4?

Sagimet Biosciences reported that its Chief Financial Officer, Thierry Chauche, sold 1,312 shares of Series A Common Stock. The transaction occurred on February 10, 2026, and involved an open-market sale primarily to cover tax withholding obligations from vested restricted stock units.

How many Sagimet (SGMT) shares did the CFO sell and at what price?

The CFO, Thierry Chauche, sold 1,312 shares of Sagimet Series A Common Stock at a price of $5.3603 per share. This open-market sale was associated with covering tax withholding obligations tied to the vesting of restricted stock units, according to the disclosure footnote.

Why were Sagimet (SGMT) shares sold by the CFO in this filing?

The filing states the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units. It also notes that these sales were automatic and not at the CFO’s discretion, indicating they were mechanically triggered to satisfy tax requirements on equity compensation.

How many Sagimet (SGMT) shares does the CFO own after this transaction?

Following the reported transaction, Chief Financial Officer Thierry Chauche beneficially owned 15,688 shares of Sagimet Series A Common Stock directly. This figure reflects his holdings after the 1,312-share sale that was executed to satisfy tax withholding tied to restricted stock unit vesting.

What is the role of the insider involved in this Sagimet (SGMT) Form 4 filing?

The insider in this Form 4 is Thierry Chauche, who serves as Chief Financial Officer of Sagimet Biosciences. The filing identifies him as an officer, not a director or 10% owner, and reports his transactions and resulting direct beneficial ownership position in the company’s common stock.